Objective: To analyze the effects of mangiferin combined with bortezomib on the proliferation, invasion, apoptosis and autophagy of human Burkitt lymphoma Raji cells, as well as the expression of CXC chemokine receptors (CXCRs) family, and explore the molecular mechanism between them to provide scientific basis for basic research and clinical work of Burkitt lymphoma.

Methods: Raji cells were intervened with different concentrations of mangiferin and bortezomib alone or in combination, then cell proliferation was detected by CCK-8 assay, cell invasion ability was detected by Transwell chamber method, cell apoptosis was detected by Annexin V/PI double-staining flow cytometry, apoptosis, autophagy and Akt/mTOR pathway protein expression were detected by Western blot, and the expression changes of CXCR family was detected by real-time quantitative PCR (RT-qPCR).

Results: Different concentrations of mangiferin intervened Raji cells for different time could inhibit cell viability in a concentration- and time-dependent manner ( =-0.682, =-0.836). When Raji cells were intervened by combination of mangiferin and bortezomib, compared with single drug group, the proliferation and invasion abilities were significantly decreased, while the apoptosis level was significantly increased ( <0.01). Mangiferin combined with bortezomib could significantly up-regulate the expression of pro-apoptotic protein Bax and down-regulate the expression of anti-apoptotic protein Bcl-2 after intervention in Raji cells. Caspase-3 was also hydrolyzed and activated, and then induced the apoptosis of Raji cells. Mangiferin combined with bortezomib could up-regulate the expression of LC3Ⅱ protein in Raji cells, and the ratio of LC3Ⅱ/LC3Ⅰ in cells was significantly up-regulated compared with single drug or control group ( <0.01). Mangiferin combined with bortezomib could significantly inhibit the phosphorylation levels of Akt and mTOR, inhibit the proliferation and invasion of Raji cells by inhibiting Akt/mTOR pathway, and induce cell autophagy and apoptosis. Mangiferin and bortezomib could down-regulate the expressions of and mRNA after single-agent intervention in Raji cells, and the down-regulations of and mRNA expression were more significant when the two drugs were combined ( <0.01). Mangiferin alone or combined with bortezomib had no significant effect on mRNA expression in Raji cells ( >0.05), while the combination of the two drugs could down-regulate the expression of ( <0.05).

Conclusion: Mangiferin combined with bortezomib can synergistically inhibit the proliferation and invasion of Raji cells, and induce autophagy and apoptosis. The mechanism may be related to the inhibition of Akt/mTOR signaling pathway, down-regulation of anti-apoptotic protein Bcl-2 and up-regulation of pro-apoptotic protein Bax, and the inhibition of the expression of CXCR family.

Download full-text PDF

Source
http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2023.05.022DOI Listing

Publication Analysis

Top Keywords

raji cells
16
mangiferin combined
8
combined bortezomib
8
burkitt lymphoma
8
expression cxc
8
cxc chemokine
8
proliferation invasion
8
apoptosis autophagy
8
cells intervened
8
concentrations mangiferin
8

Similar Publications

Liver B Cells Promotes MASLD Progression via the Apelin/APLNR System.

Int J Med Sci

January 2025

Department of Medical Laboratory Science, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China.

Investigate the role of the apelin/APLNR axis in metabolic dysfunction-associated steatotic liver disease (MASLD), focusing on the progression from metabolic dysfunction-associated simple steatotic liver (MASS) to metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, with emphasis on liver B cells. Serum samples from MASLD patients and liver tissues from hepatocellular carcinoma patients were collected to measure apelin and APLNR protein expression. C57BL/6J mouse models of varying MASLD stages were developed using a high-fat diet and CCl.

View Article and Find Full Text PDF

Objectives: To evaluate the manufacturability, efficacy and safety of allogeneic CD19 chimeric antigen receptor double-negative T cells (CD19-CAR-DNTs) as an off-the-shelf therapeutic cell product.

Methods: A membrane proteome array was used to assess the off-target binding of CD19-CAR. DNTs derived from healthy donors were transduced with lentiviral vectors encoding the CD19-CAR.

View Article and Find Full Text PDF

The increasing effective, detectable, and targeted anticancer systems are driven by the growing cancer incidence and the side effects of current drugs. Natural products like saponin and apigenin have emerged as valuable compounds for precise treatment. Recent advancements in bioactive metal-organic frameworks (MOFs) have introduced multifunctional particles suitable for cellular imaging, targeted drug delivery, and early cancer treatment.

View Article and Find Full Text PDF

Preclinical evaluation of 64Cu/177Lu-labelled anti-CD30 monoclonal antibody for theranostics in CD30-positive lymphoma.

Eur J Nucl Med Mol Imaging

December 2024

Department of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University, 95 Yong An Road, Xi Cheng District, Beijing, 100050, China.

Purpose: CD30 serves as an ideal therapeutic target for lymphoma, but its variable expression and high relapse rate pose challenges in targeted therapy. This study aims to label the anti-CD30 monoclonal antibody with Cu/Lu for immuno-positron emission tomography (immuno-PET) and radioimmunotherapy (RIT).

Methods: CD30 binding kinetics of anti-CD30-IgG (IMB16) were measured by Biolayer interferometry (BLI).

View Article and Find Full Text PDF

Unveiling CKS2: A Key Player in Aggressive B-Cell Lymphoma Progression and a Target for Synergistic Therapy.

Cancer Med

November 2024

Department of Hematology, Sun Yat-Sen Institute of Hematology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China.

Article Synopsis
  • The study aimed to analyze the expression of the CKS2 gene in Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL), focusing on its biological significance and how it relates to cancer prognosis.
  • Researchers used bioinformatics, designed specific shRNA sequences to target CKS2, and evaluated the impact on cell behavior, including proliferation and apoptosis.
  • Results indicated that higher CKS2 levels are associated with worse patient outcomes and that knocking down CKS2, especially when combined with the drug etoposide, significantly inhibited tumor cell growth and increased cancer cell death.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!